Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00195936 · ClinicalTrials.gov registry record · Phase 1
Effect of Cinacalcet on Parathyroid Hormone Secretion in Children and Adolescents With Hypophosphatemic Rickets
A Phase 1 study of Hypophosphatemic Rickets, X-Linked Dominant, sponsored by Children's Mercy Hospital Kansas City.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT00195936 is a Phase 1 study of Hypophosphatemic Rickets, X-Linked Dominant that has completed, run by Children's Mercy Hospital Kansas City. The registered enrollment target is 8 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00195936, a Phase 1 study of Hypophosphatemic Rickets, X-Linked Dominant, has completed, sponsored by Children's Mercy Hospital Kansas City.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will measure the effect of cinacalcet (Sensipar) on parathyroid hormone (PTH) secretion in children and adolescents with hypophosphatemic rickets (XLH). The investigators are seeking evidence that patients with XLH may benefit from treatment with cinacalcet by achieving better control of PTH secretion.
Conditions Studied
Interventions
- DRUG Cinacalcet
Study Locations (1)
Missouri
- Section of Pediatric Nephrology, Children's Mercy Hospitals and Clinics - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2005-06 |
| Est. Completion | 2008-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00195936
The ClinicalTrials.gov registry entry for NCT00195936 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Mercy Hospital Kansas City, which has 184 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypophosphatemic Rickets, X-Linked Dominant appearing as the primary indexed condition, and to 1 intervention - of which Cinacalcet is the first listed.
NCT00195936 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT00195936 about?
NCT00195936 is a clinical study titled "Effect of Cinacalcet on Parathyroid Hormone Secretion in Children and Adolescents With Hypophosphatemic Rickets". This study will measure the effect of cinacalcet (Sensipar) on parathyroid hormone (PTH) secretion in children and adolescents with hypophosphatemic rickets (XLH). The investigators are seeking evidence that patients with XLH may benefit from treatment with cinacalcet by achieving better control of ...
What is the current status of trial NCT00195936?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2005-06. Estimated completion is 2008-02.
What conditions does trial NCT00195936 study?
This clinical trial studies the following conditions: Hypophosphatemic Rickets, X-Linked Dominant.
What interventions are being tested in trial NCT00195936?
The interventions under investigation include: Cinacalcet (DRUG).
Who is sponsoring clinical trial NCT00195936?
This trial is sponsored by Children's Mercy Hospital Kansas City, which has 184 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00195936 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypophosphatemic Rickets, X-Linked Dominant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.